Stocktoria
LENZ Therapeutics, Inc. LENZ
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-06-25
LENZ Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -477.5% | — | — | — | — |
| Net margin | -430.3% | — | — | — | — |
| FCF margin | -366.7% | — | — | — | — |
| Return on assets | -26.8% | -23.1% | -99.4% | -31.4% | -17.6% |
| Return on equity | -28.9% | -24.4% | 75.5% | 418.1% | -18.4% |
| Current ratio | 14.23 | 20.36 | 3.63 | 21.11 | 31.44 |
Source: SEC EDGAR filings · CIK 0001815776 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.